AMGN compared with FATE: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

FATEFate Therapeutics Inc

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

FATEFate Therapeutics Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

FATE: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only FATE 8

—Baylor College of Medicineunlistedsupplier

—Dana Farber Cancer Instituteunlistedsupplier

—Memorial Sloan Kettering Cancer Centerunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—The Scripps Research Instituteunlistedsupplier

4 more · FATE chain ›

AMGNAmgen Inc

468.63▼−2.06%

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

FATEFate Therapeutics Inc

1.83▼−12.68%

Regular sessionNov 5 '26

Mkt cap$250.4MRevenue$2MQ2 FY26Revenue$7MFY25

Compare

Regular sessionNov 5 '26

AMGNAmgen Inc

FATEFate Therapeutics Inc

468.63▼−2.06%

Price

1.83▼−12.68%

$258.8B

Mkt cap

$250.4M

Q3 FY26$10.4B

Revenue

$2MQ2 FY26

FY25$36.8B

Revenue

$7MFY25

AMGN468.63▼−2.06%vsFATE1.83▼−12.68%Regular sessionNov 5 '26

Price

rebased to 0%

AMGN, solidFATE, dashed